Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2003

View Archived Issues

Potential new applications reported for the antidepressant milnacipran

Clinical trial assesses combination of NMDA antagonist and morphine in chronic pain

Effective analgesia induced by LAS-34475 in postoperative dental pain

Evidence of efficacy for erlosamide in neuropathic pain

Preclinical results for NeuGene agents against single-stranded RNA viruses

JUPITER assesses effect of Crestor on cardiovascular disease risk reduction

BlockAide/CR appears to target diverse HIV-1 strains

Pyrrolidine CCR5 receptor modulators identified by Merck

New P2Y agonists with utility in COPD therapy presented by Celltech

CV Therapeutics identifies adenosine A3 receptor agonists with utility in cancer and neutropenia

Celltech researchers describe hydroxamate-based MMP inhibitors

New series of analgesic NMDA glycine-site antagonists under study at Gruenenthal

Melacure claims melanocortin receptor modulators for obesity, inflammation, etc.

Roche scientists prepare and test new 5-HT6 receptor ligands

New antiparkinsonian adenosine A2A antagonists discovered at Sigma-Tau

New antibacterial macrolides in early development at Enanta

Photofrin approved in Canada for HGD associated with Barrett's esophagus

European approval for Nutropin AQ

Launch date set for Finacea

Fuzeon 48-week data reported, progressive distribution program planned

Novel analgesic from Otsuka useful for peripheral neuropathic pain

Antihyperalgesic effects determined for UCB-34714 in rat models of neuropathic pain

Hong Kong researchers succeed in isolating virus responsible for SARS

First findings supporting UCB-34714 as an improved antiepileptic agent

Italian investigators identify potent new ARIs with potential in diabetic complications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...